# OnCo record intrahepatic-cholangiocarcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "intrahepatic-cholangiocarcinoma" ;
  schema:name "Intrahepatic cholangiocarcinoma"@en ;
  schema:alternateName "iCCA"@en, "Intrahepatic bile duct cancer"@en, "Peripheral cholangiocarcinoma"@en, "Mass-forming cholangiocarcinoma"@en ;
  schema:description "Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."@en ;
  schema:url <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cholangiocarcinoma> ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/32203698/>, <https://pubmed.ncbi.nlm.nih.gov/32416072/>, <https://www.nejm.org/doi/full/10.1056/NEJMoa2206834>, <https://en.wikipedia.org/wiki/Cholangiocarcinoma> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/drugs/tinengotinib/>, <https://onco.cc/trials/first-308/>, <https://onco.cc/ideas/idea-btc-ctdna-fgfr-resistance/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/liver-transplant-oncology/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/drugs/zanidatamab/> ;
  onco:standardOfCare <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/fgfr2-fusion/>, <https://onco.cc/terms/hepatectomy/>, <https://onco.cc/terms/lymphadenectomy/>, <https://onco.cc/trials/bilcap/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/liver-transplant-oncology/>, <https://onco.cc/trials/topaz-1/>, <https://onco.cc/trials/keynote-966/>, <https://onco.cc/trials/abc-02/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/pairings/gemcis-plus-io-btc/>, <https://onco.cc/drugs/pemigatinib/>, <https://onco.cc/drugs/futibatinib/>, <https://onco.cc/trials/fight-202/>, <https://onco.cc/trials/foenix-cca2/>, <https://onco.cc/targets/fgfr2/>, <https://onco.cc/terms/fgfr2-fusion/>, <https://onco.cc/drugs/ivosidenib/>, <https://onco.cc/trials/claridhy/>, <https://onco.cc/targets/idh/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> .